Drug Type Synthetic peptide |
Synonyms FOXY 5 |
Target |
Action modulators |
Mechanism WNT5A modulators(Wnt family member 5A modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H42N6O12S2 |
InChIKeyWFZPJYYCTSHDJI-ATIWLJMLSA-N |
CAS Registry881188-51-8 |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colonic Cancer | Phase 2 | Spain | 12 Apr 2019 | |
| Metastatic colon cancer | Phase 1 | Denmark | 01 Apr 2016 | |
| Metastatic colon cancer | Phase 1 | United Kingdom | 01 Apr 2016 | |
| Metastatic Prostate Carcinoma | Phase 1 | Denmark | 01 Apr 2016 | |
| Metastatic Prostate Carcinoma | Phase 1 | United Kingdom | 01 Apr 2016 | |
| Metastatic breast cancer | Phase 1 | Denmark | 01 Jun 2013 |
Phase 2 | Colonic Cancer Neoadjuvant | 110 | einjnzdiwn(ayuezmwzrm) = The pathological examination of primary tumours revealed that significantly fewer patients treated with Foxy-5 exhibited venous invasion of cancer cells (p=0.0097) as well as perineural invasion (p=0.0088) uklrfsfvoc (dyhlevhddo ) View more | Positive | 26 Jun 2024 |






